Patents by Inventor Pia Norregaard
Pia Norregaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240209054Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: ApplicationFiled: September 22, 2023Publication date: June 27, 2024Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
-
Patent number: 11814417Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: GrantFiled: April 2, 2021Date of Patent: November 14, 2023Assignee: Zealand Pharma A/SInventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
-
Publication number: 20220041676Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: ApplicationFiled: April 2, 2021Publication date: February 10, 2022Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
-
Patent number: 11008375Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.Type: GrantFiled: August 27, 2018Date of Patent: May 18, 2021Assignee: Zealand Pharma A/SInventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
-
Patent number: 11001619Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: GrantFiled: February 21, 2019Date of Patent: May 11, 2021Assignee: Zealand Pharma A/SInventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
-
Publication number: 20190256569Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: ApplicationFiled: February 21, 2019Publication date: August 22, 2019Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
-
Publication number: 20190218270Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.Type: ApplicationFiled: August 27, 2018Publication date: July 18, 2019Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Jacob Ulrik FOG, Carsten Boye KNUDSEN
-
Patent number: 10253081Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: May 18, 2018Date of Patent: April 9, 2019Assignee: Zealand Pharma A/SInventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
-
Patent number: 10253078Abstract: The present invention relates to acylated GIP analogs which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: GrantFiled: October 29, 2015Date of Patent: April 9, 2019Assignee: Zealand Pharma A/SInventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
-
Publication number: 20190055296Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: May 18, 2018Publication date: February 21, 2019Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
-
Patent number: 10093713Abstract: The present invention relates to acylated GIP analogs which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.Type: GrantFiled: November 6, 2014Date of Patent: October 9, 2018Assignee: Zealand Pharma A/SInventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
-
Patent number: 9975939Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: September 24, 2015Date of Patent: May 22, 2018Assignee: Zealand Pharma A/SInventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
-
Publication number: 20170240609Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.Type: ApplicationFiled: October 29, 2015Publication date: August 24, 2017Applicant: Zealand Pharma A/SInventors: Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
-
Publication number: 20160280754Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.Type: ApplicationFiled: November 6, 2014Publication date: September 29, 2016Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Jacob Ulrik FOG, Carsten Boye KNUDSEN
-
Publication number: 20160009777Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: September 24, 2015Publication date: January 14, 2016Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
-
Patent number: 9180169Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: September 17, 2013Date of Patent: November 10, 2015Assignee: Zealand Pharma A/SInventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
-
Publication number: 20140080757Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: September 17, 2013Publication date: March 20, 2014Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/SInventors: Jakob Lind TOLBORG, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas
-
Publication number: 20060235035Abstract: Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is selected from hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, —CHO, nitrile, alkyl, alkenyl or alkynyl groups, —SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as —CH2CF3, —CF2CF3, —CF3, —OCF3, —SCF3; —SO2NH2, —SO2NHAlk, —SO2NAlk2, —SO2Alk; X is H, F, Cl, Br, I, —SCH3, —CF3, —OCF3, —SCF3, OCH3, or lower alkyl or alkenyl group; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups, arylalkoxyType: ApplicationFiled: April 8, 2003Publication date: October 19, 2006Applicant: 7TM Pharma A/SInventors: Thomas Hogberg, Emelie Bjurling, Jean-Marie Receveur, Trond Ulven, Paul Little, Christian Elling, Pia Norregaard
-
Publication number: 20060111357Abstract: The present invention relates to the use of quinoline compounds for the preparation of a pharmaceutical and/or a cosmetic composition for the treatment, prophylaxis and/or diagnosis of a condition caused by or involving a melanin-concentrating hormone. The invention also relates to novel quinoline compounds per se. The quinoline compounds have been found to interact with a melanin-concentrating hormone receptor, a MCH receptor. The compounds have modulating activity on the MCH receptor such as e.g. antagonistic, agonistic or allosteric activity and are useful for medicinal or cosmetic purposes such as, e.g. in the treatment or prevention of feeding disorders like obesity, metabolic syndrome, Type II diabetes, bulimia, etc. or in the treatment or prevention of depression.Type: ApplicationFiled: December 11, 2003Publication date: May 25, 2006Inventors: Thomas Frimurer, Trond Ulven, Thomas Hogberg, Pia Norregaard, Paul Little, Jean-Marie Receveur